CD90 or Thy-1 is an antigen co-expressed with CD34 ؉ on putative immature hematopoietic stem cells. Peak mobilization of CD34
there are multipotent as well as committed, lineage-restricted progenitor cells. 4 Further characterization of the CD34 ϩ cell population by flow cytometry can identify multipotent progenitor cells more accurately by the expression of CD45Ro, 5 and by the lack of expression of CD38, 6 CD33, 7 CD13, 8 and HLA-DR. 8, 9 Committed progenitor cells express CD34 along with antigens associated either with myeloid (CD33, CD13), 10 erythroid (CD71), 11 lymphoid (CD7, CD19), 12 or megakaryocytic lineage (CD41, CD61). 13, 14 The role of these various CD34 ϩ subsets in predicting the short-or long-term reconstitutive capacity of an autologous blood stem cell graft is not well defined. In a recent study, we found that neither CD34 ϩ 33 Ϫ , CD34 ϩ 38 Ϫ , nor CD34 ϩ 41 ϩ subsets independently predict time to recovery of neutrophils у0.5 ϫ 10 9 /l or platelets у20 ϫ 10 9 /l for unmanipulated autografts containing Ͼ5 ϫ 10 6 CD34 ϩ cells/kg. 15 If the autograft contained Ͻ5 ϫ 10 6 CD34 ϩ cells/kg, a weak association was found between the relative proportion of CD34 ϩ 33 Ϫ /total CD34 ϩ cell dose and time to platelet recovery у20 ϫ 10 9 /l. Other studies have reported stronger associations between CD34 ϩ subsets and hematopoietic engraftment. [16] [17] [18] [19] [20] CD90 or Thy-1 is an antigen co-expressed with CD34 ϩ on putative immature hematopoietic stem cells found in fetal liver, cord blood and bone marrow. 21 Due to the discrepancy in the number of CD34 ϩ 90 ϩ cells relative to CD34 ϩ 38 Ϫ cells, investigators have suggested that CD34 ϩ 90 ϩ cells contain more than just primitive progenitor cells. 22 Peak mobilization of CD34 ϩ 90 ϩ cells into the blood occurs a few days earlier than peak mobilization of total CD34 ϩ cells. [23] [24] [25] [26] Because it is not known which cell type best correlates with engraftment, and therefore, which cell type should be targeted for collection, the optimal timing for apheresis remains unclear.
The main objective of this study was to determine if CD34 ϩ 90 ϩ cells are associated with engraftment of autologous blood stem cells independent of the total CD34 ϩ cell dose, other CD34 ϩ subsets, or various clinical factors.
Patients and methods

Patients
Between February 1997 and February 1999, 134 consecutive patients aged 19-66 years (median 46 years) underwent
Bone Marrow Transplantation ABSCT in Calgary. Nine patients were excluded from analysis because of autograft processing with the CellPro CEPRATE SC System (n = 4), stem cell mobilization with cytokine only (n = 4), and death less than 7 days post ASCT, before engraftment could be evaluated (n = 1). Table 1 lists the characteristics of the remaining 125 patients who received combined chemotherapy plus G-CSF for stem cell mobilization, and whose autografts did not undergo ex vivo manipulation. These 125 patients underwent ABSCT for the following disease indications: breast cancer (n = 54), non-Hodgkin's lymphoma (n = 42), Hodgkin's lymphoma (n = 17), multiple myeloma (n = 9), and other malignancies (n = 3). Sixty-six of these 125 patients were included in a previous study assessing the association between CD34 ϩ 33 Ϫ , CD34 ϩ 38 Ϫ , and CD34 ϩ 41 ϩ subsets and hematopoietic engraftment. 15 All patients provided written informed consent for ABSCT and the institutional review board approved all studies.
Blood stem cell collection
Patients were grouped according to their initial method of autologous blood stem cell mobilization. One group of 70 patients received disease-specific, moderately intensive chemotherapy (mostly based upon cyclophosphamide 2 g/m 2 ) dosed to produce short-duration neutropenia and thrombocytopenia that would not require platelet transfusion. These patients received daily G-CSF 300 g (Ͻ70 kg) or 480 g (Ͼ70 kg) s.c. starting on day 7 or 8, and underwent apheresis on day 13 or 14. A second group of 55 patients received cyclophosphamide 5.25 g/m 2 , etopo- 27 Autologous stem cell transplantation Table 2 lists the high-dose chemotherapy regimens received by these patients. They varied according to disease and study protocol, and changed over time. There was a strong correlation between the high-dose regimen and diagnosis. Melphalan-containing regimens were used for 54 patients with lymphoma, for no patient with breast cancer, and for 10 patients with other diagnoses. Mitoxantrone-cyclophosphamide-based regimens were used for 50 patients with breast cancer but not for any other diagnosis. Autologous blood stem cells were infused on day 0. All patients received daily G-CSF 300 (Ͻ70 kg) or 480 (Ͼ70 kg) g/day s.c. from day ϩ7 post transplant until ANC Ͼ1.5.
Blood stem cell enumeration
Flow cytometric analysis was performed on an EPICS-XL (Beckman-Coulter, Hialeah, FL, USA) using a modified protocol as described previously. 15, 27 
CD34
ϩ 33 Ϫ , CD34 ϩ 38 Ϫ , CD34 ϩ 41 ϩ , and CD34 ϩ 90 ϩ subsets were measured for all 125 consecutive patients. Due to the high leukocyte count of apheresis products, approximately 10 l of sample was used for phenotyping (approximately 1 ϫ 10 6 cells per test). Purified goat immunoglobulin (Caltag, Burlingame, CA, USA) was added to each tube prior to the addition of monoclonal antibodies to prevent non-antigenmediated binding via Fc receptors. After a 10 min incubation period, CD90-FITC or MsIg-FITC (PharMingen, San Diego CA, USA), and CD34-PC5 (Beckman-Coulter) were added according to the manufacturer's guidelines, and incubated for a further 15 min at room temperature, in the dark. Samples were lysed with 2 ml of pre-warmed (37°C) ammonium lysis buffer for 2 min, washed with 2 ml of PBS-0.1% sodium azide, and centrifuged for 5 min at 250 g. Cell pellets were resuspended in 0.5 ml PBS-0.1% sodium azide and analyzed immediately on an EPICS-XL flow cytometer (Beckman-Coulter). SSClow CD34 ϩ events were displayed and the discrete cluster of CD34 ϩ stem cells was gated, excluding any spurious signal from debris, granulocytes, platelets, and unlysed red blood cells. The gated CD34 ϩ cells were subsequently displayed in a two-parameter fluorescent histogram displaying the fluorescent signals from the monoclonal antibodies of interest. Cursors were set using isotype controls as guidelines in establishing the levels of background fluorescence.
Statistics
Platelet engraftment у20 ϫ 10 9 /l and у100 ϫ 10 9 /l was defined as the first of 3 consecutive days that the platelet count was at or above the specified level without platelet transfusions. Neutrophil engraftment was defined as the first of 3 consecutive days that the sum of segmented neutrophil plus band count was у0.5 ϫ 10 9 /l. In univariate Other NHL, GCT, MB, BrCa 11 BrCa = breast cancer; CI = continuous infusion; GCT = germ cell tumor; HD = Hodgkin's disease; MB = medulloblastoma; MM = multiple myeloma; NHL = non-Hodgkin's lymphoma; TBI = total body irradiation.
analysis, Spearman's rank correlation test was used for continuous independent variables. Kruskal-Wallis rank sum test was used for categorical independent variables. Cox proportional hazards models were then built to study the effect of a predictor with other variables being simultaneously controlled. Due to the nature of the data that was not normally distributed, logarithmic transformation was made to CD34 ϩ cell dose/kg. To determine whether various CD34 ϩ subsets were independently associated with engraftment, modeling was done using the proportion of the total CD34 ϩ cell dose which was positive for the subset being analyzed (eg CD34 ϩ 41 ϩ kg divided by total CD34 ϩ kg) rather than the absolute CD34 ϩ subset/kg dose. This was done to avoid co-linearity because the total CD34 ϩ subset/kg values were highly correlated with the total CD34 ϩ cell/kg dose, whereas the proportions were not.
Cox proportional hazards models were used to determine if the following factors were independently associated with neutrophil or platelet engraftment: age, gender, number of prior chemotherapy regimens, prior radiotherapy, morphological evidence of bone marrow infiltration, stem cell mobilization regimen, high-dose conditioning regimen, use of total body irradiation, total CD34 ϩ dose/kg, and proportional dose of various CD34 ϩ cell subsets including Since the use of a particular high-dose regimen was highly correlated with diagnosis, it was felt inappropriate to analyze the effect of both on engraftment. For this reason, the high-dose regimen was chosen for analysis since it theoretically had a more direct effect on engraftment kinetics than diagnosis. Our previous study found melphalan Ϯ TBI to be associated with slightly Bone Marrow Transplantation slower engraftment than other regimens. Therefore, in the present study we analyzed the effect of the high-dose regimen by dividing patients into those who received melphalan-containing regimens vs those who received other regimens.
Results
Hematopoietic engraftment after ABSCT
The CD34
ϩ dose infused ranged from 1.1 to 70.9 ϫ 10 6 /kg (median 9.9) for the 125 patients. The median time to neutrophil recovery у0.5 ϫ 10 9 /l was 11 days (range 8-17), to platelet recovery у20 ϫ 10 9 /l was 11 days (range 8-89), and to platelet recovery у100 ϫ 10 9 /l was 15 days (range 10-185) post ABSCT. For cell doses of 1-5, 5-10, or Ͼ10 ϫ 10 6 CD34 ϩ cells/kg, the proportion of patients who achieved neutrophil engraftment by day 11 was 30, 65% and 89%, respectively (P Ͻ 0.0001), the proportion of patients who achieved platelet engraftment у20 ϫ 10 9 /l by day 11 was 30%, 47% and 76%, respectively (P = 0.0004), and the proportion of patients who achieved platelet engraftment у100 ϫ 10 9 /l by day 16 was 10%, 47% and 66%, respectively (P = 0.0001). For the 64 patients receiving melphalan-containing regimens, the total CD34 ϩ cell dose ranged from 2.2 to 70.9 ϫ 10 6 /kg (median 16.6 ϫ 10 6 /kg), neutrophil engraftment occurred from day 10 to 13 (median day 11), platelet engraftment у20 ϫ 10 9 /l occurred from day 9 to 89 (median day 11), and platelet engraftment у100 ϫ 10 9 /l occurred from day 15 to 185 (median day 18). For the 61 patients receiving regimens not containing melphalan, the total CD34 ϩ cell dose ranged 
Correlation between CD34
ϩ subsets and hematopoietic engraftment For each subset, the proportion of the total CD34 ϩ dose/kg infused is shown in the box plots of Figure 1 ϩ subsets did not significantly differ by diagnosis or by the method of blood stem cell mobilization. Spearman-rank correlation assays were applied to assess the relationship between the total number of CD34 ϩ cells/kg or the total number of a subset of CD34 ϩ cells/kg and hematopoietic engraftment (see Table 3 ). The Table 3 Correlation between hematopoietic engraftment and infused dose of total CD34 + cells or subsets of CD34 + cells using Spearman's rank correlation test
CD34
+ Subset ANC Ͼ0. ϩ 90 ϩ . Although all four CD34 ϩ subsets correlated with engraftment, the coefficients were higher for the total CD34 ϩ cell dose/kg than for any particular CD34 ϩ subset.
Multivariate analysis of factors potentially associated with hematopoietic engraftment
As shown in Table 4 , the log (CD34 ϩ dose/kg) and highdose regimen were the only factors independently associated with neutrophil and platelet engraftment by Cox proportional hazards models. These two factors accounted for 17.5% of the variance observed in neutrophil engraftment, 26.2% of the variance observed in platelet engraftment Ͼ20 ϫ 10 9 /l, and 38.2% of the variance observed in time to platelet engraftment Ͼ100 ϫ 10 9 /l. When controlling for high-dose regimen, log (CD34 ϩ cell dose/kg) explained 15.2% of the variance in neutrophil engraftment, 25.7% of the variance in platelet engraftment Ͼ20 x 10 9 /l, and 36% of the variance in platelet engraftment Ͼ100 ϫ 10 9 /l. None of the CD34 ϩ subsets were independently associated with either neutrophil or platelet engraftment regardless of whether: (1) the analysis was performed on all patients or only on those who had a low total CD34 ϩ cell dose Ͻ5 ϫ 10 6 /kg; or (2) if analyses were performed within disease subgroups (breast cancer, lymphoma, or other); or (3) if absolute CD34 ϩ subset doses/kg were analyzed instead of ratios of CD34 ϩ subset/total CD34 ϩ cell dose.
Discussion
In this study, factors independently associated with both neutrophil engraftment (у0.5 ϫ 10 9 /l) and platelet engraftment (у20 ϫ 10 9 /l and у100 ϫ 10 9 /l) were higher total CD34 ϩ dose/kg infused and high-dose regimen (melphalan-containing slower than other regimens). These data confirm previous reports of a strong correlation between CD34 ϩ cell dose/kg and hematopoietic engraftment after ABSCT. 1, 28, 29 By univariate analysis, all subsets of CD34 ϩ cells studied correlated less well with hematopoietic recovery than did the total CD34 ϩ cell dose/kg. By multivariate analysis, no CD34 ϩ subset was independently associated with hematopoietic engraftment.
We confirmed our previous report that melphalancontaining regimens are associated with slightly slower
CD34
؉ 90 ؉ cells and hematopoietic engraftment DA Stewart et al 439 Table 4 Factors independently associated with engraftment engraftment than the non-melphalan-containing regimens studied. The reason for this is unclear but may relate to damage to the marrow stroma. The data do not prove, however, that the slower engraftment following melphalan-containing regimens was directly due to the melphalan. This result may have indirectly been due to the strong association between the choice of high-dose regimen and cancer diagnosis. For example, it is possible that patients who received melphalan-containing regimens had more stem cell damage from prior cytotoxic therapy, and, therefore, had poorer quality autografts. It should be noted however, that the relative proportion of CD34 ϩ subsets did not significantly differ by cancer diagnosis. Therefore, if the reconstitutive capacity of the autograft truly did differ by cancer diagnosis, the CD34 ϩ subsets were not able to detect this difference. The total CD34 ϩ cell dose/kg did predict engraftment well, and in fact patients who received melphalan-containing high-dose regimens had slightly higher total CD34 ϩ cell doses than patients who received other regimens.
Previous studies have reported that the highest levels of CD34 ϩ 90 ϩ cells occur on the first day of blood stem cell apheresis, and then decrease on subsequent days. Because 94% of our patients had only a single apheresis procedure, varying proportions of CD34 ϩ subsets with successive days of apheresis do not confound our results. Our study could not detect an independent association between the CD34 ϩ 90 ϩ subset dose and early hematopoietic engraftment. Whether the CD34 ϩ 90 ϩ or any other CD34 ϩ subset provides more accurate information on long-term hematopoietic reconstitutive capacity of mobilized blood stem cells still remains unknown. As in our previous report, the total CD34 ϩ cell dose/kg correlated better with engraftment than the dose of any CD34 ϩ subset. Possible reasons why our results conflict with those of other investigators have been previously described. 15 These possibilities include different statistical methods with logarithmic transformation of the total CD34 ϩ dose, single apheresis procedures, heterogeneous patient populations, use of various high-dose and mobilization regimens, small sample sizes, possible differences in methods of CD34 ϩ subset enumeration and different apheresis techniques. Contrary to our previous study, we did not detect any effect of the CD34 ϩ 33 Ϫ subset on platelet ϩ subsets and hematopoietic engraftment following ex vivo autograft purging or expansion, as well as the possible relationship between CD34 ϩ subsets and long-term hematopoietic engraftment following ABSCT.
